Lord, Abbett & Co
RCKT icon

Lord, Abbett & Co’s Rocket Pharmaceuticals RCKT Stock Holding History

Lord, Abbett & Co’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,197,182
Closed -$23.8M – 574
2023
Q2 		$23.8M Buy
1,197,182
+41,844
+4% +$845K 0.08% 313
2023
Q1 		$19.8M Buy
1,155,338
+619,750
+116% +$12.1M 0.07% 350
2022
Q4 		$10.5M Buy
535,588
+639
+0.1% +$11.8K 0.04% 420
2022
Q3 		$8.54M Buy
534,949
+271,018
+103% +$4.23M 0.03% 421
2022
Q2 		$3.63M Buy
263,931
+18,239
+7% +$217K 0.01% 519
2022
Q1 		$3.9M Sell
245,692
-1,043,313
-81% -$18M 0.01% 571
2021
Q4 		$28.1M Buy
1,289,005
+79,437
+7% +$2.17M 0.06% 349
2021
Q3 		$36.2M Sell
1,209,568
-438,903
-27% -$16M 0.09% 329
2021
Q2 		$73M Sell
1,648,471
-3,723
-0.2% -$162K 0.18% 173
2021
Q1 		$73.3M Buy
1,652,194
+62,142
+4% +$3.41M 0.19% 177
2020
Q4 		$87.2M Sell
1,590,052
-1,343
-0.1% -$49K 0.23% 131
2020
Q3 		$36.4M Buy
1,591,395
+254,673
+19% +$6.28M 0.12% 271
2020
Q2 		$28M Sell
1,336,722
-176,632
-12% -$3.18M 0.1% 320
2020
Q1 		$21.1M Buy
1,513,354
+492,820
+48% +$9.76M 0.09% 314
2019
Q4 		$23.2M Buy
1,020,534
+595,821
+140% +$9.95M 0.08% 368
2019
Q3 		$4.95M Sell
424,713
-28,767
-6% -$357K 0.02% 634
2019
Q2 		$6.8M Buy
453,480
+133,119
+42% +$2.32M 0.02% 625
2019
Q1 		$5.62M Sell
320,361
-7,592
-2% -$120K 0.02% 642
2018
Q4 		$4.86M Sell
327,953
-84,783
-21% -$1.41M 0.02% 655
2018
Q3 		$10.2M Buy
412,736
+56,222
+16% +$1.22M 0.03% 618
2018
Q2 		$7M Buy
+356,514
New +$6.74M 0.02% 680

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Lord, Abbett & Co's RCKT Position: Q3 2023 in Review

Lord, Abbett & Co sold out of Rocket Pharmaceuticals (RCKT) in Q3 2023, closing a stake of 1,197,182 shares — an estimated $23.8M sold.

Lord, Abbett & Co first reported a position in RCKT in Q2 2018 and held it in 21 quarters. The position peaked at $87.2M in Q4 2020. 175 funds tracked by Wall St. Rank hold RCKT as of Q3 2023.

  • Lord, Abbett & Co reported no remaining Rocket Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,197,182 Rocket Pharmaceuticals shares in Q3 2023, an estimated $23.8M.
  • Lord, Abbett & Co first reported a position in Rocket Pharmaceuticals in Q2 2018 and held it in 21 quarters.
  • Lord, Abbett & Co's Rocket Pharmaceuticals position peaked at $87.2M in Q4 2020.
  • 175 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2023.

Based on Lord, Abbett & Co's 13F filing for Q3 2023, filed 13 Nov 2023.